静脉血栓栓塞症的危险因素和危险分层诊断 - 开云网页登录

主管：开云网页登录
主办：开云网页登录医学院附属瑞金医院
ISSN 1671-2870 CN 31-1876/R

诊断学理论与实践››2019,Vol. 18››Issue (1): 10-15.doi:10.16150/j.1671-2870.2019.01.003

• 专家论坛 •上一篇下一篇

静脉血栓栓塞症的危险因素和危险分层诊断

门剑龙, 任静

天津医科大学总医院精准医学中心，天津 300052

收稿日期:2018-01-20出版日期:2019-02-25发布日期:2019-02-25

Received:2018-01-20Online:2019-02-25Published:2019-02-25

摘要/Abstract

中图分类号:

R559

门剑龙, 任静. 静脉血栓栓塞症的危险因素和危险分层诊断[J]. 诊断学理论与实践, 2019, 18(1): 10-15.

图/表4

表1

Caprini静脉血栓风险评估量表

1分	2分	3分	5分
年龄41~60岁	年龄61~74岁	年龄≥75岁	脑卒中（<1个月）
小手术	关节镜手术	静脉血栓病史	择期关节置换术
体质量指数>25 kg/m²	大型开放手术（>45 min）	静脉血栓家族史	髋、骨盆或下肢骨折
下肢肿胀	腹腔镜手术（>45 min）	凝血因子V Leiden突变	急性脊髓损伤（<1个月）
静脉曲张	恶性肿瘤	凝血酶原 G20210A突变
妊娠或产后	卧床>72 h	狼疮抗凝物阳性
有不明原因的或者习惯性流产史	石膏固定	抗心磷脂抗体阳性
口服避孕药或激素替代疗法	中央静脉通路	血清同型半胱氨酸升高
脓毒症（<1个月）		肝素诱导的血小板减少症
严重肺病，包括肺炎（<1个月）		其他先天性或获得性血栓形成倾向
肺功能异常
急性心肌梗死
充血性心力衰竭（<1个月）
炎症性肠病史
卧床患者

表1

表2

表3

表4

参考文献19

[1]	Zhang Z, Lei J, Shao X, et al. Trends in Hospitalization and In-Hospital Mortality From VTE, 2007 to 2016, in China[J]. Chest, 2019, 155(2):342-353.
[2]	Zhai Z, Kan Q, Li W, et al. VTE Risk Profiles and Prophylaxis in Medical and Surgical Inpatients: The Identification of Chinese Hospitalized Patients′ Risk Profile for Venous Thromboembolism (DissolVE-2)-A Cross-sectional Study[J]. Chest, 2019, 155(1):114-122.
[3]	Margaglione M, Grandone E. Population genetics of venous thromboembolism. A narrative review[J]. Thromb Haemost, 2011, 105(2):221-231.
[4]	Zhu T, Ding Q, Bai X, et al. Normal ranges and genetic variants of antithrombin, protein C and protein S in the general Chinese population. Results of the Chinese Hemostasis Investigation on Natural Anticoagulants Study I Group[J]. Haematologica, 2011, 96(7):1033-1040.
[5]	Tang L, Wang HF, Lu X, et al. Common genetic risk factors for venous thrombosis in the Chinese population[J]. Am J Hum Genet, 2013, 92(2):177-187.
[6]	Tang L, Hu Y. Ethnic diversity in the genetics of venous thromboembolism[J]. Thromb Haemost, 2015, 114(5):901-909.
[7]	刘凤林, 张太平. 中国普通外科围手术期血栓预防与管理指南[J]. 中国实用外科杂志, 2016, 36(5):469-474.
[8]	中华医学会呼吸病学分会肺栓塞与肺血管病学组, 中国医师协会呼吸医师分会肺栓塞与肺血管病工作委员会, 全国肺栓塞与肺血管病防治协作组. 肺血栓栓塞症诊治与预防指南[J]. 中华医学杂志, 2018, 98(14):1060-1087.
[9]	《中国血栓性疾病防治指南》专家委员会. 中国血栓性疾病防治指南[J]. 中华医学杂志, 2018, 98(36):2861-2888.
[10]	Kearon C, Akl EA, Comerota AJ, et al. Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines[J]. Chest, 2012, 141(2 Suppl):e419S-e496S.
[11]	Streiff MB, Holmstrom B, Ashrani A, et al. Cancer-Associated Venous Thromboembolic Disease, Version 1.2015[J]. J Natl Compr Canc Netw, 2015, 13(9):1079-1095.
[12]	Ay C, Dunkler D, Marosi C, et al. Prediction of venous thromboembolism in cancer patients[J]. Blood, 2010, 116(24):5377-5382.
[13]	中华医学会血液学分会血栓与止血学组. 易栓症诊断中国专家共识(2012年版)[J]. 中华血液学杂志, 2012, 33(11):982.
[14]	Baglin T, Gray E, Greaves M, et al. Clinical guidelines for testing for heritable thrombophilia[J]. Br J Haematol, 2010, 149(2):209-220.
[15]	Reynaud Q, Lega JC, Mismetti P, et al. Risk of venous and arterial thrombosis according to type of antiphospholipid antibodies in adults without systemic lupus erythematosus: a systematic review and meta-analysis[J]. Autoimmun Rev, 2014, 13(6):595-608.
[16]	Moulis G, Audemard-Verger A, Arnaud L, et al. Risk of thrombosis in patients with primary immune thrombocytopenia and antiphospholipid antibodies: A systematic review and meta-analysis[J]. Autoimmun Rev, 2016, 15(3):203-209.
[17]	Pengo V, Tripodi A, Reber G, et al. Update of the guidelines for lupus anticoagulant detection. Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis[J]. J Thromb Haemost, 2009, 7(10):1737-1740.
[18]	Clinical and Laboratory Standards Institute.Laboratory Testing for the Lupus Anticoagulant H60-A; Approved Guideline, 2014, Vol. 34 No. 6.[M]. Wayne, 2014.
[19]	中国医师协会心血管内科医师分会血栓防治专业委员会《中华医学杂志》编辑委员会. 肝素诱导的血小板减少症中国专家共识(2017)[J]. 中华医学杂志, 2018, 98(6):408-417.

相关文章5

编辑推荐

Metrics

本文评价